Neuphoria Therapeutics (NEUP) Expected to Announce Earnings on Tuesday

Neuphoria Therapeutics (NASDAQ:NEUP) is expected to be announcing its results before the market opens on Tuesday, May 19th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its quarterly earnings results on Tuesday, February 17th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.21). On average, analysts expect Neuphoria Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neuphoria Therapeutics Price Performance

Shares of NEUP opened at $5.17 on Tuesday. Neuphoria Therapeutics has a 12 month low of $3.64 and a 12 month high of $21.40. The stock has a market cap of $27.87 million, a PE ratio of -1.17 and a beta of 0.72. The stock’s 50-day moving average is $4.67 and its two-hundred day moving average is $4.38.

Institutional Trading of Neuphoria Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC acquired a new position in Neuphoria Therapeutics in the third quarter worth about $216,000. Geode Capital Management LLC lifted its stake in Neuphoria Therapeutics by 33.3% during the fourth quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock worth $67,000 after purchasing an additional 4,325 shares during the last quarter. Commonwealth Equity Services LLC acquired a new position in Neuphoria Therapeutics in the fourth quarter worth $43,000. Persistent Asset Partners Ltd boosted its holdings in Neuphoria Therapeutics by 173.1% in the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock worth $52,000 after purchasing an additional 8,495 shares during the period. Finally, Diadema Partners LP raised its holdings in shares of Neuphoria Therapeutics by 133.1% during the fourth quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock worth $194,000 after purchasing an additional 28,548 shares during the period. Institutional investors and hedge funds own 15.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, January 22nd. Zacks Research raised shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Neuphoria Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $21.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.